Prakash Bhatia, MD
Psychiatry · National City, CANPI 1164464137
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $25,100 of the $36,524 with a category attached, or 68.7%. Alkermes, Inc. accounts for 60.3% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2019 at $29,987 and has fallen 93.6% since, to $1,917 in 2025. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 377 payments — averaging $96.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$22K
- Johnson & Johnson$8K
- AbbVie$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Sunovion Pharmaceuticals Inc.$786
- Teva Pharmaceuticals USA, Inc.$778
- plus $3K from 18 others
What the payments were for
- Speaking & faculty fees$25,10069%
- Travel & lodging$1,5024%
- Food & beverage$9,92127%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 68 | $22,011 |
| Johnson & Johnson | 46 | $7,739 |
| AbbVie(2 entities) | 46 | $1,086 |
| Otsuka America Pharmaceutical, Inc. | 41 | $1,083 |
| Sunovion Pharmaceuticals Inc. | 39 | $786 |
| Teva Pharmaceuticals USA, Inc. | 30 | $778 |
| Lundbeck LLC | 29 | $550 |
| Neurocrine Biosciences, Inc. | 11 | $477 |
| Axsome Therapeutics, Inc. | 4 | $378 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 15 | $336 |
| E.r. Squibb & Sons, L.L.C. | 10 | $272 |
| Indivior Inc. | 11 | $250 |
| Vanda Pharmaceuticals Inc. | 5 | $213 |
| Neuronetics, Inc. | 8 | $192 |
| Corium, LLC | 2 | $154 |
| Jazz Pharmaceuticals Inc. | 3 | $37 |
| Ironshore Pharmaceuticals Inc. | 2 | $33 |
| Acadia Pharmaceuticals Inc | 1 | $28 |
| Biogen | 1 | $24 |
| Merck | 1 | $23 |
| Livanova USA, Inc. | 1 | $20 |
| Vertical Pharmaceuticals, LLC | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Noven Therapeutics, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$36,524 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 27 | $83,823 |
| VraylarCariprazine Hcl | 18 | $24,818 |
| Lurasidone Hcl | 37 | $10,041 |
| Aripiprazole | 94 | $8,680 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 26 | $6,733 |
| Quetiapine Fumarate | 166 | $3,559 |
| Divalproex Sodium | 80 | $3,518 |
| Divalproex Sodium ErDivalproex Sodium | 31 | $1,917 |
| Risperidone | 124 | $1,897 |
| Fluvoxamine Maleate | 18 | $1,780 |
| Carbamazepine | 33 | $1,471 |
| Perphenazine | 19 | $1,430 |
| Trazodone Hcl | 111 | $1,041 |
| Clomipramine Hcl | 11 | $917 |
| Benztropine Mesylate | 65 | $884 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $7,739 | $83,82327 claims |
| AbbVieVraylar | $1,086 | $24,81818 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,954 psychiatry providers in California.
Other psychiatry in National City
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
- Bibi DasStanford$1.4M
- Konstantinos TripodisBurbank$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.